Clinical Trial Finder

Inclusion Criteria:

• - 1.

Subjects must have the ability to understand and willingness to sign a written informed consent document.

• - 2.

Subjects must have histologically advanced or cytologically confirmed metastatic or unresectable mucosal melanoma;

• - 3.

Subjects have not received standard systemic therapy; patients have disease progression 6 months or more after the end of neoadjuvant or adjuvant therapy (except nab-paclitaxel), and can be enrolled in the clinical study;

• - 4.

Subject must have at least 1 unidimensional measurable disease by RECIST 1.1;

• - 5.

Subjects must be age 18 years or older;

• - 6.

Subjects must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

• - 7.

Life expectancy ≥3 months based on investigator's judgement；

• - 8.

Subjects must have adequate organ function;

• - 9.

Women of childbearing potential need to have a negative pregnancy test and need to take contraceptive/contraceptive measures including their partners.

Exclusion Criteria:

• - 1.

Subjects have another active invasive malignancy within 5 years；

• - 2.

The subject has received anti-tumor therapy or other investigational drug therapy or traditional Chinese medicine (herbal medicine) with anti-tumor indications prior to the first dose;

• - 3.

Subjects with a history of ≥ Grade 3 immune-related adverse events resulted from previous immunotherapy.

• - 4.

History of clinically significant sensitivity or allergy ；

• - 5.

Primary central nervous system (CNS) malignancies or symptomatic CNS metastases.；

• - 6.

History of (non-infectious) pneumonitis that required corticosteroids or current pneumonitis, or history of interstitial lung disease；

• - 7.

Subjects have active pulmonary embolism with hemodynamic changes 12 weeks before the first dose;

• - 8.

Subjects must not have a known or suspected history of autoimmune disease within 3 years prior to the first dose of study treatment;

• - 9.

Subjects have clinically uncontrolled diseases;

• - 10.

Subjects have severe cardiovascular disease;

• - 11.

Subjects have evidence of active infection;

• - 12.

Subjects must not have a known or suspected history of an autoimmune disorder；

• - 13.

Major surgery within 4 weeks prior to study entry and Minor surgery within 2 weeks prior to the first dose.

• - 14.

Any condition that the investigator assesses as inappropriate for participation in the study.

Arms

Experimental: Intervention/treatment

YH003 in combination with pebolizumab and albumin paclitaxel in first-line treatment of patients with unresectable/metastatic mucosal melanoma

Interventions

Drug: - YH003

YH003 will be administered intravenously over 30 minutes every 21-day cycle.

Drug: - Pembrolizumab

Pembrolizumab will be administered intravenously over 30 minutes every 21-day cycle.

Drug: - albumin paclitaxel

Albumin paclitaxel will be administered intravenously over 30 minutes every 21-day cycle.